Neuropathic pain is usually managed pharmacologically, rather than with botulinum toxin type A (BTX-A). However, medications commonly fail to relieve pain effectively or have intolerable side effects. We present the case of a 62-year-old man diagnosed with an intracranial chondrosarcoma, which was removed surgically and treated with radiation therapy. He suffered from neuropathic pain despite combined pharmacological therapy with gabapentin, amitriptyline, tramadol, diazepam, and duloxetine because of adverse effects. BTX-A (100 units) was injected subcutaneously in the most painful area in the posterior left thigh. Immediately after the injection, his pain decreased significantly from 6/10 to 2/10 on a visual analogue scale. Pain relief lasted for 12 weeks. This case report describes intractable neuropathic pain caused by a brain tumor that was treated with subcutaneous BTX-A, which is a useful addition for the management of neuropathic pain related to a brain tumor.
Citations
Citations to this article as recorded by
The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications Marco Papagni, Monica Renga, Selene Mogavero, Paolo Veronesi, Maurizio Cavallini Toxins.2025; 17(1): 31. CrossRef
A Systematic Review of Non-Opioid Pain Management in Chiari Malformation (Type 1) Patients: Current Evidence and Novel Therapeutic Opportunities Awinita Barpujari, Alina Kiley, Jennifer A. Ross, Erol Veznedaroglu Journal of Clinical Medicine.2023; 12(9): 3064. CrossRef
Botulinum Toxin Treatment for Cancer-Related Disorders: A Systematic Review Delaram Safarpour, Bahman Jabbari Toxins.2023; 15(12): 689. CrossRef
Botulinum Neurotoxins and Cancer—A Review of the Literature Shivam O. Mittal, Bahman Jabbari Toxins.2020; 12(1): 32. CrossRef
Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains